We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Combination Treatment Helps Overcomes Anal Incontinence

By HospiMedica International staff writers
Posted on 24 Oct 2011
A new study claims that a combination of therapies for fecal incontinence is more effective than the current standard treatment.

Researchers at Justus-Liebig-University (JLU; Giessen, Germany), Lübeck University (Germany), and other institutions conducted a multicenter randomized trial involving 80 patients with anal incontinence, comparing a combination of electromyography biofeedback (EMG-BF) and amplitude-modulated medium-frequency stimulation--known as triple-target treatment (3T)--with the standard treatment, low-frequency stimulation (LFS). More...
Thirty-nine patients were randomized to 3T, and 41 to LFS. The primary endpoint was Cleveland Clinic Score (CCS) after self-training at home with either 3T or LFS, in two 20-minute sessions per day for six months. The secondary endpoints included the proportion of patients regaining continence, and the patients´ quality of life (QoL).

The results showed that after six months of treatment, the CCS mean score was 3.1 in the 3T group, compared to 9.6 in the LFS group; the median improvement in the CCS at six months compared to baseline was 7 points greater in the 3T group than in the LFS group. Anal continence was regained by 54% of the 3T patients, versus none of the LFS patients, and QoL scores were higher in all dimensions in the 3T group than in the LFS group. No major adverse effects occurred in either group. The study was published in the October 2011 issue of Deutsches Ärzteblatt International.

“3T is superior to LFS in the treatment of anal incontinence,” concluded lead author Thilo Schwandner, MD, of JLU, and colleagues. “The available evidence suggests that the success of 3T is based on the combined effect of biofeedback and medium-frequency stimulation. LFS of the type applied in this trial has no effect; 3T should be used in routine clinical practice instead of LFS.”

Combination therapy involves targeted training, biofeedback, and electrical stimulation. First, the phasic voluntary musculature is trained using EMG-biofeedback, so that patients can learn to activate the correct muscle groups to achieve continence. In a separate component, the smooth muscle (which cannot be voluntarily contracted) is treated with medium-frequency stimulation, which is less painful than low-frequency stimulation.

Related Links:

Justus-Liebig-University
Lubeck University




Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.